MiNK Therapeutics, Inc. (INKT): Price and Financial Metrics
GET POWR RATINGS... FREE!
INKT Stock Price Chart Interactive Chart >
INKT Price/Volume Stats
| Current price | $1.67 | 52-week high | $22.16 |
| Prev. close | $1.36 | 52-week low | $1.20 |
| Day low | $1.44 | Volume | 28,100 |
| Day high | $1.69 | Avg. volume | 71,336 |
| 50-day MA | $2.15 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 56.05M |
MiNK Therapeutics, Inc. (INKT) Company Bio
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate includes AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
Latest INKT News From Around the Web
Below are the latest news stories about MiNK Therapeutics Inc that investors may wish to consider to help them evaluate INKT as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayGood morning, investor! |
Could The MiNK Therapeutics, Inc. (NASDAQ:INKT) Ownership Structure Tell Us Something Useful?Every investor in MiNK Therapeutics, Inc. ( NASDAQ:INKT ) should be aware of the most powerful shareholder groups... |
MiNK Therapeutics to Participate at Upcoming B. Riley Securities Virtual Oncology ConferenceNEW YORK, Jan. 12, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on January 27th, 2022, at 12:00 pm |
Agenus COO resigns to lead subsidiary MiNK Therapeutics (NASDAQ:INKT)Agenus (AGEN) announced that Dr. Jennifer Buell, its President and Chief Operating Officer, resigned from her position at the company to become President and Chief Executive Officer at |
Sorrento Therapeutics (NASDAQ:SRNE) and MiNK Therapeutics (NASDAQ:INKT) Head to Head ReviewSorrento Therapeutics (NASDAQ:SRNE) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership. Profitability This table compares Sorrento Therapeutics and MiNK Therapeutics net margins, return on equity and [] |
INKT Price Returns
| 1-mo | -25.45% |
| 3-mo | -35.52% |
| 6-mo | -87.42% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -62.56% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...